Neurocrine Bio. (NBIX) PT Lowered to $177 at JPMorgan
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/30/2026
- Nasdaq hits near three-month low as Amazon, Intel rattle AI trade
- Amazon burns cash, Intel flags weak PC demand as AI boom's costs ripple across markets
- Bitcoin, cryptocurrency prices fall after Binance reports security issue
- Higher yields now hurting AI stock bull as bond markets police capex: BofA
- Oil prices set for fourth straight monthly gains as tanker attack highlights supply risks
Tweet
Share
E-mailGet Alerts NBIX Hot Sheet
Price: $147.43 +0.72%
Rating Summary:
31 Buy, 6 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 11 | Down: 48 | New: 9
Rating Summary:
31 Buy, 6 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 11 | Down: 48 | New: 9
Join SI Premium – FREE
JPMorgan analyst Anupam Rama lowered the price target on Neurocrine Bio. (NASDAQ: NBIX) to $177.00 (from $179.00) while maintaining a Overweight rating.
You May Also Be Interested In
- Neurocrine Biosciences Launches Interactive Educational Resources to Support Clinical Learning in Classic Congenital Adrenal Hyperplasia
- Eli Lilly (LLY) PT Raised to $1,600 at RBC Capital After an 'Impressive Quarter'
- Stryker (SYK) PT Lowered to $375 at RBC Capital
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
